L-Dopa

Type: Keyphrase
Name: L-Dopa
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

AbbVie 2nd-qtr 2014 earnings beat forecasts

US drugmaker AbbVie (NYSE: ABBV), which has just clinched a $55 billion deal to acquire Ireland-based Shire (The Pharma Letters passim), reported second-quarter 2014 financial results, with earnings beating consensus estimates.Net earnings for the quarter ... [Published Pharma Letter - Jul 26 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Long-term Parkinson's treatment sheds bad rep

Many doctors delay prescribing an effective treatment for Parkinson’s disease out of fear that the drug will cause side effects if given too early. That fear may be unfounded, a new study suggests.Since the 1960s, doctors have prescribed levodopa to ease ... [Published Science News Online - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Best Initial Therapy for Parkinson Disease

This is the Medscape Neurology Minute. I am Dr. Alan Jacobs. Researchers from the University of Oxford in the United Kingdom have published a large, randomized controlled trial directly comparing levodopa with dopamine agonists and monoamine oxidase type ... [Published Diabetes Care - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.If all goes as planned on the regulatory front, the candidate, ... [Published Fierce Drug Delivery - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

Can a Pill Increase Creativity?

A new study shows that Parkinson’s patients on the drug levodopa are much more creative than their peers. But don’t hold your breath for a cure for writer’s block.Could a prescription for creativity be on the horizon?According to a new study, a link has ... [Published Daily Beast - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 3 reports

The Creativity Pill

Neurologist Rivka Inzelberg recently noticed that her patients with Parkinson's disease seemed to be authoring more novels than older people tend to author. Looking closer, poems and paintings also seemed to be pouring out of afflicted patients, in a ... [Published Wall Street Business Network - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Largest Clinical Trial of Three Different Types of Drugs Finds Levodopa Therapy Most Effective to Start for Parkinson's Disease

Back to Top | Article Outline ARTICLE IN BRIEF FigureImage ToolsIn one of the largest randomized trials to compare three different classes of Parkinson's disease drugs, investigators found that levodopa achieves somewhat better control of motor symptoms ... [Published Neurology Today - Jul 18 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

L-dopa medication could be helpful in treatment of phobias, post-traumatic stress disorder

A drug used to treat Parkinson's disease could also help people with phobias or post-traumatic stress disorder (PTSD). Scientists of the Translational Neurosciences (FTN) Research Center at Johannes Gutenberg University Mainz (JGU) are currently exploring ... [Published Science Daily - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Rescuing Parkinson’s Patients from Helplessness May ‘Rescue’ Their Caregivers

NEW YORK – (DGIwire) — Those who care for loved ones with progressive diseases involving dementia—such as Alzheimer’s and Parkinson’s—are twice as likely to suffer depression than those providing care for non-dementia patients, according to a University ... [Published Boston Globe - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

[Articles] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

Tozadenant at 120 or 180 mg twice daily was generally well tolerated and was effective at reducing off-time. Further investigation of tozadenant treatment in phase 3 trials is warranted. ... [Published The Lancet Neurology online - Jul 07 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

[Comment] Adenosine A2A receptor antagonists in Parkinson's disease: still in the running

For more than 40 years, levodopa has been the gold standard for symptomatic drug treatment in Parkinson's disease. However, most patients treated with levodopa eventually develop motor complications, including levodopa-induced dyskinesias and response ... [Published The Lancet Neurology online - Jul 07 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Comprehensive Mass Analysis for Chemical Processes, a Case Study with L-Dopa Manufacture

To evaluate the “Greenness” of chemical processes in route selection and process development, we propose a comprehensive mass analysis to inform the stakeholders from different fields. This is carried out by characterizing the mass intensity for each ... [Published RSC - Jul 02 2014]

Quotes

...a strategic action that will further enhance our long-term growth prospects," said Richard Gonzalez, chairman and chief executive of, AbbVie.   "Last month, we raised our 2014 earnings-per-share guidance, reflecting strong underlying business performance. We continue to expect positive trends for the second half of the year, as well as additional progress from our pipeline, including the expected US approval of our interferon-free HCV combination."
"I am pleased to accept the organizers' offer to present at #C4CT," said Dr. Arendt. "After being the first to identify the scientific principles underpinning Amarantus' diagnostic blood test LymPro, I have continued my research into Alzheimer's disease with a strong focus on human tissue evaluation from Alzheimer's patients. I believe there is a need to take a much broader perspective in thinking about Alzheimer's, and I am pleased to have this unique forum to share my perspective with the world."
"In one embodiment, a biodegradable, multi-layered gastroretentive drug formulation for the sustained release of an active agent in the stomach and gastrointestinal tract of a patient, includes an internal layer containing an active agent and a degradable polymer which is not instantly soluble in gastric fluid. The internal layer includes a first side and an opposing second side. At least one membrane is covering the internal layer. The membrane comprises at least one polymeric combination of a hydrophilic polymer and a polymer, insoluble in gastric media, the membrane being hydratable in the gastric media. The membrane is directly secured to and covers both sides of the internal layer and has a predetermined length greater than 20 mm in a planar orientation, the membrane and internal layer being arranged in an accordion folded orientation sufficiently compact to be placed within a capsule dissolvable within the stomach of a patient and simulated gastric media. The membrane and internal layer unfold from the accordion folded orientation to a length of at least 20 mm within 30 minutes of being exposed to gastric media. The membrane permits passage of gastric media from the environment to the internal layer and permits passage of the active agent from the internal layer through the membrane to the environment."

More Content

All (123) | News (94) | Reports (0) | Blogs (28) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
AbbVie 2nd-qtr 2014 earnings beat forecasts [Published Pharma Letter - Jul 26 2014]
Global Parkinson's Disease Market : 2014-2018 [Published MarketResearch.com - Jul 26 2014]
Long-term Parkinson's treatment sheds bad rep [Published Science News Online - Jul 25 2014]
Health Column: Get your mojo going with energy ... [Published Glenwood Independent - Jul 24 2014]
Best Initial Therapy for Parkinson Disease [Published Diabetes Care - Jul 24 2014]
Amarantus and BSI Announce Dr. Thomas Arendt as... [Published Good Day Sacramento - Jul 23 2014]
Patent Issued for Carbidopa/Levodopa Gastrorete... [Published Pharmacy Choice - Jul 23 2014]
Consider This Before Taking St. John’s Wort [Published Care2 - Jul 23 2014]
Don’t Snooze? You Lose [Published Arthritis Self-Management - Jul 22 2014]
Phase II trial kicks off for sublingually deliv... [Published Fierce Drug Delivery - Jul 22 2014]
Can a Pill Increase Creativity? [Published Daily Beast - Jul 21 2014]
Parkinson's Patients Taking Dopamine Drugs Find... [Published Medical Daily - Jul 21 2014]
Science Stumbles onto a Creativity Pill | IdeaFeed [Published DailyMe.Com - Jul 21 2014]
Amarantus Discusses New Independent Peer-Review... [Published Pettinga Financial Advisors - Jul 18 2014]
The Creativity Pill [Published Wall Street Business Network - Jul 18 2014]
Largest Clinical Trial of Three Different Types... [Published Neurology Today - Jul 18 2014]
FDA approves droxidopa to treat neurogenic orth... [Published Drugtopics.com - Jul 17 2014]
The Creativity Pill [Published Epoch Times - Jul 17 2014]
The Creativity Pill [Published Atlantic Monthly - Jul 17 2014]
Visual Outcome of Mega-dose IV Corticosteroids ... [Published General Medicine eJournal - Jul 15 2014]
Amarantus Announces Positive Analytical Perform... [Published SPi World News - Jul 14 2014]
7 Weird Body Symptoms—Solved [Published Prevention - Jul 14 2014]
Vasectomy raises prostate cancer risk [Published Iran Daily - Jul 11 2014]
Addressing Side Effects of Mainstream Treatments [Published Drug Discovery and Development - Jul 11 2014]
Sleep disturbances may be early warning sign of... [Published Business Standard India - Jul 11 2014]
Sleep disturbances, common in Parkinson's disea... [Published EurekAlert! - Jul 10 2014]
Parkinson's Medication Could Be Helpful In Trea... [Published BioSpace - Jul 10 2014]
L-dopa medication could be helpful in treatment... [Published Science Daily - Jul 10 2014]
( AMBS ) Amarantus BioScience Holdings AAIC 201... [Published Scottrade - Jul 09 2014]
Findings from University Hospital Update Knowle... [Published HispanicBusiness.com - Jul 09 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Articles] Tozadenant (SYN115) in patients with... [Published The Lancet Neurology online - Jul 07 2014]
Tozadenant at 120 or 180 mg twice daily was generally well tolerated and was effective at reducing off-time. Further investigation of tozadenant treatment in phase 3 trials is warranted. ...
[Comment] Adenosine A2A receptor antagonists in... [Published The Lancet Neurology online - Jul 07 2014]
For more than 40 years, levodopa has been the gold standard for symptomatic drug treatment in Parkinson's disease. However, most patients treated with levodopa eventually develop motor complications, including levodopa-induced dyskinesias and response ...
Please Read 25 Years of Research Pays Off [Published HealthBoards - Jul 06 2014]
Before I start I want to stress that this is written after 25 years of my husbands battle with RLS that progressed to his entire left side of his body. He was seriously contemplating suicide as he could no longer take the pain ,physical and emotional ...
Levodopa Shows Slight Edge As Initial Treatment... [Published MedlinePlus Health News - Jun 26 2014]
Source: Parkinson's Disease FoundationRelated MedlinePlus Page: Parkinson's Disease ...
BIO THALAMUS PHASE (Adenosinum Cyclophosphoricu... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 16, 2014 EST ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Biotie: Tozadenant Phase 2b Parkinson's disease... [Published GlobeNewswire: Advertising News - Jul 08 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.